Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Ipsen SA

Merck KGaA Well-Equipped Against War And Raw Material Shortages

Despite the impact of the war in Ukraine and spiralling costs, as well as lower COVID-19-based revenues, the German group is forecasting a healthy financial performance for full-year 2022.

Sales & Earnings Supply Chain

Intercept Offloads Ex-US Business To Advanz, May Be Doubling Down On NASH In US

Still working to refile its NASH fibrosis NDA 22 months after an FDA complete response letter, Intercept gets $405m up front for its ex-US business, including commercial rights to Ocaliva in PBC.

Deals Business Strategies

DoD Contracts For OTC COVID-19 Tests Go To Abbott, iHealth, Roche Diagnostics, Siemens

Department of Defense awards series of contracts to meet Biden administration’s pledge to supply a billion at-home COVID-19 rapid tests.

Coronavirus COVID-19 OTC Devices

Antios Says Its Novel Hepatitis B Mechanism Can Help Toward Functional Cure

First-in-class active-site polymerase inhibitor yields Phase Ib/IIa data showing suppression of HBV DNA. It also demonstrated a good safety profile with normalization of liver enzymes.

Clinical Trials Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Clementia Pharmaceuticals, Inc.
    • Ipsen Bioscience, Inc.
    • Sterix
    • Tercica, Inc.
    • Syntaxin Ltd.
    • OctreoPharm Sciences GmbH
    • Octagen Corporation
UsernamePublicRestriction

Register